Latest Breaking News On - Safety run in cohorts - Page 1 : comparemela.com

Teclistamab plus daratumumab and lenalidomide had a manageable safety profile in patients with transplant-ineligible, newly diagnosed multiple myeloma.

United statesTeclistamab tecvayliSalomon manierAmerican society for transplantationLille university hospitalInternational myeloma working groupCommon terminology criteriaAdverse eventsAmerican societyCellular therapySafety run in cohorts